US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Zenas BioPharma Inc.

32.32

+1.053.36%

Volume:527.68K

Turnover:16.84M

Market Cap:2.11B

PE:-3.57

High:32.77

Open:31.51

Low:29.88

Close:31.27

52wk High:44.60

52wk Low:13.50

Shares:65.18M

Float Shares:47.02M

Volume Ratio:0.92

T/O Rate:1.12%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-9.0522

EPS(LYR):-8.4448

ROE:-199.04%

ROA:-34.42%

PB:8.53

PE(LYR):-3.83

Loading ...

Overview Company News Filings

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

Assessing Zenas BioPharma (ZBIO) Valuation After A Strong Year And Recent Share Price Weakness

Simply Wall St.

Zenas BioPharma Submits Obexelimab Application in Immunoglobulin G4-Related Disease

MT Newswires Live

Zenas BioPharma submits FDA BLA for obexelimab in IgG4-related disease

Zenas Biopharma Announces Submission of Biologics License Application (Bla) to U.S. FDA for Obexelimab in Igg4-Rd

THOMSON REUTERS

What Zenas BioPharma (ZBIO)'s First-in-Human Oral IL-17 Inhibitor Trial Means For Shareholders

Simply Wall St.

Stock Track | Zenas BioPharma Soars 6.45% in Pre-Market on Positive Phase 3 Trial Results for Obexelimab

Zenas BioPharma presents Phase 3 obexelimab IgG4-RD data at EULAR congress

Zenas Biopharma Announces Upcoming Presentation of Results From Phase 3 Indigo Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (Igg4-Rd) at Eular 2026 Congress

THOMSON REUTERS

Stock Track | Zenas BioPharma Soars 9.17% on CEO Share Purchase and Phase 3 Trial Progress

Zenas BioPharma CEO Leon O. Moulder Jr acquires 60,000 shares for $1.01 million

Zenas BioPharma grants 51,075 inducement RSUs to new hires

Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS Segment

Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.

Wall Street Analysts Are Bullish on Top Healthcare Picks

How Zenas BioPharma’s First-in-Human Oral IL-17 Trial Could Reframe Zenas BioPharma (ZBIO) Investors

Simply Wall St.

Zenas BioPharma Is Maintained at Equal-Weight by Morgan Stanley

Wedbush Sticks to Its Buy Rating for Zenas BioPharma, Inc. (ZBIO)

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/ZBIO/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ZBIO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":32.32,"timestamp":1788206400000,"preClose":31.27,"halted":0,"volume":527681,"delay":0,"changeRate":0.03357850975375762,"floatShares":47024692,"shares":65176700,"eps":-9.052203,"marketStatus":"Pre-Mkt","change":1.05,"latestTime":"09-01 07:43:54 EDT","open":31.51,"high":32.77,"low":29.88,"amount":16837732.925244,"amplitude":0.092421,"askPrice":36.9,"askSize":100,"bidPrice":31.85,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-9.052203,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1788269400000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":32.32,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":32.32,"preClose":32.32,"latestTime":"19:30 EDT","volume":30954,"amount":1000426.078168,"timestamp":1788219002875,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.9208591086888067,"impliedVol":0.5896,"impliedVolPercentile":0.0797},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ZBIO\",,,,,undefined,":{"symbol":"ZBIO","floatShares":47024692,"roa":"-34.42%","roe":"-199.04%","lyrEps":-8.444814,"volumeRatio":0.9208591086888067,"shares":65176700,"dividePrice":0,"high":32.77,"amplitude":0.092421,"preClose":31.27,"low":29.88,"week52Low":13.5,"pbRate":"8.53","psRate":"2106.51","week52High":44.6,"institutionHeld":0,"latestPrice":32.32,"committee":-0.980198,"eps":-9.052203,"divideRate":0,"volume":527681,"delay":0,"ttmEps":-9.052203,"open":31.51,"prevYearClose":36.31,"prevWeekClose":31.27,"prevMonthClose":32.32,"prevQuarterClose":25.38,"fiveDayClose":31.65,"twentyDayClose":31.13,"sixtyDayClose":18.38},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ZBIO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2026-08-13","symbol":"ZBIO","fiscalQuarterEnding":"2026/06","expectedEps":-0.89,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1786593600000,"reportTimeType":"pre","actualEps":-1.77},{"market":"US","date":"2026-05-13","symbol":"ZBIO","fiscalQuarterEnding":"2026/03","expectedEps":-1.37,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1778644800000,"reportTimeType":"pre","actualEps":-1.46},{"market":"US","date":"2026-03-16","symbol":"ZBIO","fiscalQuarterEnding":"2025/12","expectedEps":-1.22,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1773633600000,"reportTimeType":"pre","actualEps":-4.54},{"market":"US","date":"2025-11-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/09","expectedEps":-0.87,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1762923600000,"reportTimeType":"pre","actualEps":-1.22},{"market":"US","date":"2025-08-12","symbol":"ZBIO","fiscalQuarterEnding":"2025/06","expectedEps":-1.02,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1754971200000,"reportTimeType":"pre","actualEps":-1.25}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ZBIO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ZBIO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.625,"buy":0.25,"hold":0.125,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":0.625,"analysts":8,"updateTime":1767931200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ZBIO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ZBIO","date":"2026-08-31","current":-3.570402,"percent":0.430612,"low":-19.592941,"twenty":-7.357957,"median":-3.88256,"eighty":-2.619118,"high":-1.802568,"avg":-5.29957,"sd":3.710357,"marketCap":2038076128},"quantilePoints":[{"date":"2024-09-13","current":-8.364044,"twenty":-11.189626,"median":-10.130033,"eighty":-9.07044,"marketCap":457989962},{"date":"2024-09-20","current":-12.731934,"twenty":-12.968841,"median":-12.731934,"eighty":-9.523082,"marketCap":697162515},{"date":"2024-09-27","current":-12.564791,"twenty":-13.484804,"median":-12.909978,"eighty":-12.029776,"marketCap":688010267},{"date":"2024-10-04","current":-14.275075,"twenty":-13.747873,"median":-12.811872,"eighty":-12.31335,"marketCap":781660299},{"date":"2024-10-11","current":-13.008553,"twenty":-13.941177,"median":-13.027627,"eighty":-12.397648,"marketCap":712309358},{"date":"2024-10-18","current":-16.373229,"twenty":-14.273549,"median":-13.29848,"eighty":-12.477586,"marketCap":896548905},{"date":"2024-10-25","current":-17.845752,"twenty":-15.022781,"median":-13.503182,"eighty":-12.59822,"marketCap":977179818},{"date":"2024-10-31","current":-16.022265,"twenty":-16.022265,"median":-13.891034,"eighty":-12.731934,"marketCap":877331175},{"date":"2024-11-08","current":-15.961228,"twenty":-15.961228,"median":-14.267446,"eighty":-12.811872,"marketCap":873988961},{"date":"2024-11-15","current":-6.06727,"twenty":-16.022265,"median":-14.202594,"eighty":-12.564791,"marketCap":782495852},{"date":"2024-11-22","current":-3.382919,"twenty":-15.961228,"median":-13.807463,"eighty":-11.896022,"marketCap":436298426},{"date":"2024-11-29","current":-3.729636,"twenty":-15.955124,"median":-13.496851,"eighty":-6.578437,"marketCap":481014835},{"date":"2024-12-06","current":-3.402361,"twenty":-15.898664,"median":-13.178717,"eighty":-4.851473,"marketCap":438805888},{"date":"2024-12-13","current":-2.997318,"twenty":-15.744546,"median":-13.008553,"eighty":-3.729636,"marketCap":386567092},{"date":"2024-12-20","current":-3.162575,"twenty":-15.636205,"median":-12.771903,"eighty":-3.606503,"marketCap":407880521},{"date":"2024-12-27","current":-3.256545,"twenty":-15.585849,"median":-12.510288,"eighty":-3.394584,"marketCap":419999921},{"date":"2025-01-03","current":-2.91955,"twenty":-15.427152,"median":-12.339512,"eighty":-3.24488,"marketCap":376537243},{"date":"2025-01-10","current":-3.007039,"twenty":-15.189107,"median":-10.412935,"eighty":-3.188498,"marketCap":387820823},{"date":"2025-01-17","current":-2.520987,"twenty":-15.022781,"median":-6.676265,"eighty":-3.159983,"marketCap":325134267},{"date":"2025-01-24","current":-2.715408,"twenty":-14.870188,"median":-6.06727,"eighty":-3.071846,"marketCap":350208890},{"date":"2025-01-31","current":-2.469142,"twenty":-14.351372,"median":-4.794107,"eighty":-2.968155,"marketCap":318447701},{"date":"2025-02-07","current":-2.54367,"twenty":-14.313224,"median":-3.888412,"eighty":-2.841781,"marketCap":328059640},{"date":"2025-02-14","current":-2.313605,"twenty":-14.275075,"median":-3.716674,"eighty":-2.653842,"marketCap":298388004},{"date":"2025-02-21","current":-2.530708,"twenty":-14.268972,"median":-3.643766,"eighty":-2.622086,"marketCap":326387998},{"date":"2025-02-28","current":-2.141867,"twenty":-14.163683,"median":-3.476889,"eighty":-2.54367,"marketCap":276238754},{"date":"2025-03-07","current":-2.35573,"twenty":-14.007233,"median":-3.332693,"eighty":-2.517747,"marketCap":303820838},{"date":"2025-03-14","current":-2.324434,"twenty":-13.840892,"median":-3.246824,"eighty":-2.465902,"marketCap":364908203},{"date":"2025-03-21","current":-2.26852,"twenty":-13.569102,"median":-3.188498,"eighty":-2.360915,"marketCap":356130342},{"date":"2025-03-28","current":-2.138053,"twenty":-13.499383,"median":-3.165816,"eighty":-2.351842,"marketCap":335648668},{"date":"2025-04-04","current":-2.076814,"twenty":-13.408148,"median":-3.159335,"eighty":-2.284767,"marketCap":326034820},{"date":"2025-04-11","current":-1.80523,"twenty":-13.315978,"median":-3.071846,"eighty":-2.26652,"marketCap":283399498},{"date":"2025-04-17","current":-2.21793,"twenty":-13.154764,"median":-2.997318,"eighty":-2.257224,"marketCap":348188468},{"date":"2025-04-25","current":-2.657256,"twenty":-13.051602,"median":-2.943853,"eighty":-2.261324,"marketCap":417157373},{"date":"2025-05-02","current":-3.077944,"twenty":-13.023813,"median":-2.968155,"eighty":-2.26639,"marketCap":483200324},{"date":"2025-05-09","current":-2.4756,"twenty":-13.008271,"median":-2.943853,"eighty":-2.269325,"marketCap":388639550},{"date":"2025-05-16","current":-2.503456,"twenty":-12.890356,"median":-2.890387,"eighty":-2.270833,"marketCap":407464932},{"date":"2025-05-23","current":-2.942974,"twenty":-12.763909,"median":-2.866084,"eighty":-2.272453,"marketCap":479001383},{"date":"2025-05-30","current":-2.570283,"twenty":-12.665077,"median":-2.835832,"eighty":-2.278934,"marketCap":418341820},{"date":"2025-06-06","current":-2.470042,"twenty":-12.521189,"median":-2.721889,"eighty":-2.297829,"marketCap":402026489},{"date":"2025-06-13","current":-2.90956,"twenty":-12.426717,"median":-2.835832,"eighty":-2.31327,"marketCap":473562940},{"date":"2025-06-20","current":-2.392933,"twenty":-12.365673,"median":-2.76689,"eighty":-2.315238,"marketCap":389476234},{"date":"2025-06-27","current":-2.608837,"twenty":-12.215932,"median":-2.714219,"eighty":-2.322158,"marketCap":424616947},{"date":"2025-07-03","current":-2.577994,"twenty":-11.896022,"median":-2.691086,"eighty":-2.323707,"marketCap":419596845},{"date":"2025-07-11","current":-3.102331,"twenty":-8.929847,"median":-2.679496,"eighty":-2.324434,"marketCap":504938576},{"date":"2025-07-18","current":-3.387633,"twenty":-8.364044,"median":-2.699206,"eighty":-2.336288,"marketCap":551374518},{"date":"2025-07-25","current":-4.194702,"twenty":-6.676265,"median":-2.718649,"eighty":-2.349239,"marketCap":682733850},{"date":"2025-08-01","current":-4.037914,"twenty":-6.187126,"median":-2.829882,"eighty":-2.35573,"marketCap":657214999},{"date":"2025-08-08","current":-3.804019,"twenty":-6.06727,"median":-2.865865,"eighty":-2.35573,"marketCap":619145893},{"date":"2025-08-15","current":-3.987237,"twenty":-5.542498,"median":-2.90956,"eighty":-2.36209,"marketCap":705768845},{"date":"2025-08-22","current":-4.02768,"twenty":-4.889717,"median":-2.928692,"eighty":-2.362211,"marketCap":712927599},{"date":"2025-08-29","current":-3.868286,"twenty":-4.698498,"median":-2.950685,"eighty":-2.372371,"marketCap":684713689},{"date":"2025-09-05","current":-4.039575,"twenty":-4.396216,"median":-2.982091,"eighty":-2.374493,"marketCap":715033114},{"date":"2025-09-12","current":-4.798483,"twenty":-4.881439,"median":-2.99503,"eighty":-2.389351,"marketCap":849365013},{"date":"2025-09-19","current":-4.629572,"twenty":-4.881439,"median":-3.063777,"eighty":-2.399463,"marketCap":819466690},{"date":"2025-09-26","current":-4.429735,"twenty":-4.835595,"median":-3.074895,"eighty":-2.402603,"marketCap":784094028},{"date":"2025-10-03","current":-4.984046,"twenty":-4.911724,"median":-3.083269,"eighty":-2.409912,"marketCap":882211057},{"date":"2025-10-10","current":-6.604159,"twenty":-5.180553,"median":-3.135974,"eighty":-2.413574,"marketCap":1168982288},{"date":"2025-10-17","current":-5.759607,"twenty":-5.320916,"median":-3.162575,"eighty":-2.420654,"marketCap":1019490677},{"date":"2025-10-24","current":-5.949928,"twenty":-5.76722,"median":-3.174048,"eighty":-2.42495,"marketCap":1053178928},{"date":"2025-10-31","current":-9.035303,"twenty":-6.083769,"median":-3.188498,"eighty":-2.432369,"marketCap":1599311910},{"date":"2025-11-07","current":-9.81546,"twenty":-6.198298,"median":-3.245204,"eighty":-2.444339,"marketCap":1737405107},{"date":"2025-11-14","current":-10.08009,"twenty":-6.457611,"median":-3.282468,"eighty":-2.446909,"marketCap":1914199059},{"date":"2025-11-21","current":-9.848299,"twenty":-7.258864,"median":-3.371139,"eighty":-2.451734,"marketCap":1870182143},{"date":"2025-11-28","current":-10.976161,"twenty":-8.972029,"median":-3.394997,"eighty":-2.453948,"marketCap":2084362015},{"date":"2025-12-05","current":-10.772637,"twenty":-9.459248,"median":-3.515773,"eighty":-2.459247,"marketCap":2045713016},{"date":"2025-12-12","current":-11.366249,"twenty":-9.83041,"median":-3.643766,"eighty":-2.466418,"marketCap":2158439264},{"date":"2025-12-19","current":-9.913314,"twenty":-9.980024,"median":-3.678075,"eighty":-2.469682,"marketCap":1882528351},{"date":"2025-12-26","current":-12.202958,"twenty":-10.134363,"median":-3.729636,"eighty":-2.472265,"marketCap":2317329596},{"date":"2026-01-02","current":-10.263827,"twenty":-10.232168,"median":-3.760324,"eighty":-2.476253,"marketCap":1949090517},{"date":"2026-01-09","current":-4.638651,"twenty":-10.207521,"median":-3.79333,"eighty":-2.479511,"marketCap":880875114},{"date":"2026-01-16","current":-5.633657,"twenty":-10.159019,"median":-3.831007,"eighty":-2.483289,"marketCap":1069825778},{"date":"2026-01-23","current":-5.766513,"twenty":-10.142278,"median":-3.88256,"eighty":-2.488034,"marketCap":1095054986},{"date":"2026-01-30","current":-5.902195,"twenty":-10.122491,"median":-3.950232,"eighty":-2.490604,"marketCap":1120820986},{"date":"2026-02-06","current":-5.938943,"twenty":-10.119664,"median":-3.975342,"eighty":-2.498305,"marketCap":1127799277},{"date":"2026-02-13","current":-7.380571,"twenty":-10.08009,"median":-4.008147,"eighty":-2.503456,"marketCap":1401563024},{"date":"2026-02-20","current":-7.637803,"twenty":-9.946669,"median":-4.026371,"eighty":-2.50452,"marketCap":1450411065},{"date":"2026-02-27","current":-7.451239,"twenty":-9.897484,"median":-4.035344,"eighty":-2.514003,"marketCap":1414982815},{"date":"2026-03-06","current":-7.140299,"twenty":-9.857345,"median":-4.041954,"eighty":-2.520051,"marketCap":1355935733},{"date":"2026-03-13","current":-6.925469,"twenty":-9.824447,"median":-4.068124,"eighty":-2.528764,"marketCap":1315139567},{"date":"2026-03-20","current":-3.549457,"twenty":-9.816065,"median":-4.041954,"eighty":-2.535893,"marketCap":1340761298},{"date":"2026-03-27","current":-3.365681,"twenty":-9.764845,"median":-4.035344,"eighty":-2.542374,"marketCap":1271342335},{"date":"2026-04-02","current":-3.206266,"twenty":-9.752191,"median":-4.02768,"eighty":-2.54367,"marketCap":1211125146},{"date":"2026-04-10","current":-3.351146,"twenty":-9.585134,"median":-4.008147,"eighty":-2.555011,"marketCap":1265851823},{"date":"2026-04-17","current":-3.426736,"twenty":-9.459248,"median":-3.975342,"eighty":-2.562572,"marketCap":1294404871},{"date":"2026-04-24","current":-2.91178,"twenty":-9.318941,"median":-3.950232,"eighty":-2.56484,"marketCap":1099887227},{"date":"2026-05-01","current":-3.042488,"twenty":-9.220114,"median":-3.88256,"eighty":-2.568711,"marketCap":1149260207},{"date":"2026-05-08","current":-3.034614,"twenty":-9.118797,"median":-3.818719,"eighty":-2.573367,"marketCap":1146285931},{"date":"2026-05-15","current":-2.806581,"twenty":-9.04377,"median":-3.782641,"eighty":-2.576966,"marketCap":1193220825},{"date":"2026-05-22","current":-2.946168,"twenty":-8.972029,"median":-3.74498,"eighty":-2.576966,"marketCap":1252566199},{"date":"2026-05-29","current":-2.756092,"twenty":-8.703526,"median":-3.716674,"eighty":-2.577994,"marketCap":1171755477},{"date":"2026-06-05","current":-2.729363,"twenty":-8.073548,"median":-3.672934,"eighty":-2.577994,"marketCap":1160391469},{"date":"2026-06-12","current":-2.637295,"twenty":-7.609535,"median":-3.597675,"eighty":-2.580331,"marketCap":1121248775},{"date":"2026-06-18","current":-2.759062,"twenty":-7.566764,"median":-3.544789,"eighty":-2.584211,"marketCap":1173018144},{"date":"2026-06-26","current":-3.663405,"twenty":-7.560564,"median":-3.528998,"eighty":-2.58741,"marketCap":1557500410},{"date":"2026-07-02","current":-4.157898,"twenty":-7.541694,"median":-3.549457,"eighty":-2.594231,"marketCap":1767734556},{"date":"2026-07-10","current":-4.370248,"twenty":-7.462546,"median":-3.643766,"eighty":-2.595516,"marketCap":1858015285},{"date":"2026-07-17","current":-4.193537,"twenty":-7.451239,"median":-3.672934,"eighty":-2.596017,"marketCap":1782886566},{"date":"2026-07-24","current":-4.601902,"twenty":-7.448412,"median":-3.716674,"eighty":-2.598756,"marketCap":1956503353},{"date":"2026-07-31","current":-4.791978,"twenty":-7.400923,"median":-3.74498,"eighty":-2.598756,"marketCap":2037314075},{"date":"2026-08-07","current":-4.777128,"twenty":-7.389051,"median":-3.770746,"eighty":-2.606821,"marketCap":2031000738},{"date":"2026-08-14","current":-3.929032,"twenty":-7.382267,"median":-3.79905,"eighty":-2.610296,"marketCap":1903160311},{"date":"2026-08-21","current":-4.254657,"twenty":-7.371525,"median":-3.831007,"eighty":-2.614149,"marketCap":2060887981},{"date":"2026-08-28","current":-4.389213,"twenty":-7.360218,"median":-3.875423,"eighty":-2.618299,"marketCap":2126064704},{"date":"2026-08-31","current":-4.207563,"twenty":-7.357957,"median":-3.88256,"eighty":-2.619118,"marketCap":2038076128}],"updateTime":1788263034569},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ZBIO\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640921618","title":"Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2640921618","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640921618?lang=en_us&edition=fundamental","pubTime":"2026-06-03 07:05","pubTimestamp":1780441500,"startTime":"0","endTime":"0","summary":"- The INDIGO study met its primary and all key secondary endpoints with statistically significant results - - Obexelimab significantly lowered the total amount of glucocorticoid use and reduced glucoc","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305741/0/en/Zenas-BioPharma-Announces-Data-from-the-Registrational-Phase-3-INDIGO-Trial-of-Obexelimab-in-Immunoglobulin-G4-Related-Disease-IgG4-RD-Simultaneously-Presented-at-the-EULAR-2026-Co.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639601567","title":"Assessing Zenas BioPharma (ZBIO) Valuation After A Strong Year And Recent Share Price Weakness","url":"https://stock-news.laohu8.com/highlight/detail?id=2639601567","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639601567?lang=en_us&edition=fundamental","pubTime":"2026-05-31 00:08","pubTimestamp":1780157299,"startTime":"0","endTime":"0","summary":"Zenas BioPharma (ZBIO), a clinical-stage immunology specialist, continues to attract attention after a year in which the stock’s total return is reported at 93.28%, contrasting with a year-to-date decline of 46.67%.\nSee our latest analysis for Zenas BioPharma.\nAt the latest share price of $18.40, Zenas BioPharma’s recent 7 day and 90 day share price returns show declines, yet its 1 year total shareholder return of 93.28% still points to earlier gains, indicating that momentum has faded...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/assessing-zenas-biopharma-zbio-valuation-after-a-strong-year","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/assessing-zenas-biopharma-zbio-valuation-after-a-strong-year","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638698263","title":"Zenas BioPharma Submits Obexelimab Application in Immunoglobulin G4-Related Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2638698263","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638698263?lang=en_us&edition=fundamental","pubTime":"2026-05-28 20:07","pubTimestamp":1779970036,"startTime":"0","endTime":"0","summary":"Zenas BioPharma  said Thursday it submitted a biologics license application to the US Food and Drug Administration for obexelimab in immunoglobulin G4-related disease, a chronic fibro-inflammatory disease affecting multiple organ systems.Obexelimab is an investigational bifunctional monoclonal antibody designed to bind both CD19 and FcgRIIb to inhibit B cell function, the company said.The application is based on results from a phase 3 registrational trial that showed a 56% reduction in the risk of IgG4-RD flare compared with placebo during the 52-week randomized placebo-controlled period, according to the company.Shares of Zenas BioPharma were up more than 1% pre-bell Thursday.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638466067","title":"Zenas BioPharma submits FDA BLA for obexelimab in IgG4-related disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2638466067","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638466067?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:22","pubTimestamp":1779967354,"startTime":"0","endTime":"0","summary":"Zenas BioPharma submitted a BLA to the FDA seeking approval of obexelimab for IgG4-related disease.Filing backed by Phase 3 INDIGO data showing a 56% reduction in flare risk versus placebo over 52 weeks .Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief on May 28, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nNDLcclrKj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638667415","title":"Zenas Biopharma Announces Submission of Biologics License Application (Bla) to U.S. FDA for Obexelimab in Igg4-Rd","url":"https://stock-news.laohu8.com/highlight/detail?id=2638667415","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638667415?lang=en_us&edition=fundamental","pubTime":"2026-05-28 19:05","pubTimestamp":1779966300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260528:nTUA30HZ1C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638301541","title":"What Zenas BioPharma (ZBIO)'s First-in-Human Oral IL-17 Inhibitor Trial Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2638301541","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638301541?lang=en_us&edition=fundamental","pubTime":"2026-05-25 00:19","pubTimestamp":1779639554,"startTime":"0","endTime":"0","summary":"Zenas BioPharma recently reported that the first subject has been dosed in a Phase 1 trial of ZB021, an oral small‑molecule IL-17AA/AF inhibitor being tested in healthy volunteers in China in partnership with InnoCare Pharma.\nThis program targets a space where no oral IL-17 inhibitors are currently approved or in late-stage development globally, potentially offering a differentiated option for autoimmune and inflammatory diseases.\nNext, we’ll examine how advancing ZB021 into Phase 1,...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/what-zenas-biopharma-zbios-first-in-human-oral-il-17-inhibit","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/what-zenas-biopharma-zbios-first-in-human-oral-il-17-inhibit","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151355812","title":"Stock Track | Zenas BioPharma Soars 6.45% in Pre-Market on Positive Phase 3 Trial Results for Obexelimab","url":"https://stock-news.laohu8.com/highlight/detail?id=1151355812","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151355812?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:23","pubTimestamp":1779189784,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. (ZBIO) shares surged 6.45% in pre-market trading on Tuesday, driven by positive clinical development news for its lead autoimmune disease therapy.The company announced that...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636085840","title":"Zenas BioPharma presents Phase 3 obexelimab IgG4-RD data at EULAR congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2636085840","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636085840?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:07","pubTimestamp":1779188827,"startTime":"0","endTime":"0","summary":"Zenas BioPharma will present Phase 3 INDIGO trial results for obexelimab in IgG4-related disease at the EULAR 2026 Congress in London on June 4, 2026.The trial met its primary endpoint, showing a 56% reduction in flare risk versus placebo over 52 weeks .Obexelimab also delivered statistically significant improvements on key secondary measures, including time to first flare requiring rescue therapy, complete remission rate, and lower cumulative glucocorticoid rescue use.Safety data showed fewer grade 3 or higher adverse events versus placebo  with no new safety signals.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL5gxT3P:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00BN0W2T93.GBP","LU2210150020.SGD","SG9999014021.USD","SG9999014005.SGD","LU0314104364.USD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","NDAQ","IE00BKPKM429.USD","BK4112","SG9999014039.USD","LU2095319765.USD","SG9999014013.SGD","BK4588","ZBIO","LU2210149790.SGD","IE00BN0W2W23.USD","BK4139","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636858454","title":"Zenas Biopharma Announces Upcoming Presentation of Results From Phase 3 Indigo Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (Igg4-Rd) at Eular 2026 Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2636858454","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636858454?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:05","pubTimestamp":1779188700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nTUABFGYRP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144972324","title":"Stock Track | Zenas BioPharma Soars 9.17% on CEO Share Purchase and Phase 3 Trial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1144972324","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144972324?lang=en_us&edition=fundamental","pubTime":"2026-05-19 09:39","pubTimestamp":1779154765,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. (ZBIO) experienced a significant surge of 9.17% during post-market trading on Monday. The biopharmaceutical company's shares rallied following two key positive developments that...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636883853","title":"Zenas BioPharma CEO Leon O. Moulder Jr acquires 60,000 shares for $1.01 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2636883853","media":"Reuters","labels":["shareholding","insiderTrades","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636883853?lang=en_us&edition=fundamental","pubTime":"2026-05-19 09:13","pubTimestamp":1779153187,"startTime":"0","endTime":"0","summary":"Zenas BioPharma CEO Leon O. Moulder Jr. reported an indirect purchase of 60,000 common shares at a weighted average price of $16.88.Indirect beneficial ownership tied to the reported holdings totaled 96,928 shares following the transaction.Separately disclosed positions included 1.79 million shares held indirectly, with 423,155 shares held directly.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zenas Biopharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 18, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260519:nNDL99h4M5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Zenas BioPharma CEO Leon O. Moulder Jr acquires 60,000 shares for $1.01 million","news_tag":"shareholding,insiderTrades,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009895","title":"Zenas BioPharma grants 51,075 inducement RSUs to new hires","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009895","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009895?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:15","pubTimestamp":1779135323,"startTime":"0","endTime":"0","summary":"Zenas BioPharma granted 51,075 restricted stock units to newly hired employees on May 15.The awards vest in four equal installments, with 25% scheduled to vest on May 15 in each year from 2027 through 2030.Vesting is contingent on continued service through each vesting date, under the company’s 2026 Inducement Plan and individual award agreements.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nNDL9LmLHP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","SG9999014021.USD","IE00BN0W2W23.USD","SG9999014039.USD","IE00BKPKM429.USD","NDAQ","IE00BGHQF748.EUR","BK4585","LU2095319765.USD","LU2210150020.SGD","IE00B3QW5Z07.USD","BK4139","ZBIO","SG9999014005.SGD","LU0314104364.USD","SG9999014013.SGD","BK4588","BK4112","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009833","title":"Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009833","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009833?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:15","pubTimestamp":1779135300,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260518:nTUAGKTZG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636009330","title":"Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2636009330","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636009330?lang=en_us&edition=fundamental","pubTime":"2026-05-19 04:15","pubTimestamp":1779135300,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., May  18, 2026  (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/18/3297026/0/en/Zenas-BioPharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636070152","title":"Zenas BioPharma Advances Phase 3 Orelabrutinib Trial in Tough MS Segment","url":"https://stock-news.laohu8.com/highlight/detail?id=2636070152","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636070152?lang=en_us&edition=fundamental","pubTime":"2026-05-19 00:30","pubTimestamp":1779121834,"startTime":"0","endTime":"0","summary":"Zenas BioPharma, Inc. ($ZBIO) announced an update on their ongoing clinical study. This phase 3 study, titled “A Phase 3, Randomized, Double-blind,...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/zenas-biopharma-advances-phase-3-orelabrutinib-trial-in-tough-ms-segment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/zenas-biopharma-advances-phase-3-orelabrutinib-trial-in-tough-ms-segment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1363072403.SGD","LU2089284900.SGD","LU0053666078.USD","LU1244550221.USD","LU2089283258.USD","LU0106831901.USD","LU0234570918.USD","LU1162221912.USD","LU0106261372.USD","BK4139","BK4516","BK4127","LU2271345857.HKD","LU1732799900.SGD","LU0795875169.SGD","LU0210528500.USD","LU0006306889.USD","LU1732800096.USD","LU2023251221.USD","LU0390134368.USD","LU0912757837.SGD","LU1720051017.SGD","IE00BZ1G4Q59.USD","BK4504","LU1548497426.USD","LU2487616109.SGD","LU2028103732.USD","LU2264538146.SGD","LU1074936037.SGD","LU0267386448.USD","LU2111349929.HKD","BK4581","LU1989772923.USD","LU2133065610.SGD","LU0320765646.SGD","ZBIO","LU0528227936.USD","LU0795875086.SGD","LU1720051108.HKD","LU0314104364.USD","LU1244550577.SGD","IE00BKVL7J92.USD","LU1064131342.USD","LU1668664300.SGD","LU0971096721.USD","LU0882574139.USD","LU1244550494.USD","LU1988902786.USD","BK4585","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635957085","title":"Zenas BioPharma Price Target Maintained With a $44.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2635957085","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635957085?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:46","pubTimestamp":1778841960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 15, 2026 06:46 ET (10:46 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635085586","title":"Wall Street Analysts Are Bullish on Top Healthcare Picks","url":"https://stock-news.laohu8.com/highlight/detail?id=2635085586","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635085586?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:40","pubTimestamp":1778841616,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Zenas BioPharma, Inc. (ZBIO), Monopar Therapeutics I...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-173?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wall-street-analysts-are-bullish-on-top-healthcare-picks-blurbs-news-173?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","LU0128526141.USD","BLSG","LABU","BLSX","BK4581","ZBIO","BK4139","BK4112","MNPR","XBI","BK4137","BK4585","LU0029874061.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635706269","title":"How Zenas BioPharma’s First-in-Human Oral IL-17 Trial Could Reframe Zenas BioPharma (ZBIO) Investors","url":"https://stock-news.laohu8.com/highlight/detail?id=2635706269","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635706269?lang=en_us&edition=fundamental","pubTime":"2026-05-15 13:47","pubTimestamp":1778824020,"startTime":"0","endTime":"0","summary":"Zenas BioPharma recently dosed the first subject in a Phase 1 trial of ZB021, an oral IL-17AA/AF inhibitor being evaluated for safety, tolerability, and pharmacokinetics in healthy volunteers in China, with early data expected by year-end 2026.\nThis first-in-human study underscores ZB021’s potential as a differentiated oral alternative to injectable IL-17 biologics for autoimmune and inflammatory diseases, supported by preclinical data showing anti-inflammatory activity and favorable ADME...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/how-zenas-biopharmas-first-in-human-oral-il-17-trial-could-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-zbio/zenas-biopharma/news/how-zenas-biopharmas-first-in-human-oral-il-17-trial-could-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["ZBIO","ISBC","BK4211","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635742611","title":"Zenas BioPharma Is Maintained at Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2635742611","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635742611?lang=en_us&edition=fundamental","pubTime":"2026-05-15 01:37","pubTimestamp":1778780220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ZBIO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 14, 2026 13:37 ET (17:37 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635486067","title":"Wedbush Sticks to Its Buy Rating for Zenas BioPharma, Inc. (ZBIO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635486067","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635486067?lang=en_us&edition=fundamental","pubTime":"2026-05-14 21:17","pubTimestamp":1778764664,"startTime":"0","endTime":"0","summary":"Wedbush analyst David Nierengarten maintained a Buy rating on Zenas BioPharma, Inc. today and set a price target of $45.00. Nierengarten covers the...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-its-buy-rating-for-zenas-biopharma-inc-zbio-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/wedbush-sticks-to-its-buy-rating-for-zenas-biopharma-inc-zbio-blurbs-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":3,"totalSize":111,"code":"91000000","status":"200"}]}}